Search Results

Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the World Economic Forum to SCOPE 2025.

Covis Group S.à r.l. announced the completion of its acquisition of AMAG Pharmaceuticals, Inc. through the successful tender offer for all of the outstanding shares of common stock of AMAG at $13.75 per share in cash and subsequent merger.

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced AMAG and Palatin Technologies, Inc. have mutually terminated the January 2017 license agreement pursuant to which AMAG was granted exclusive rights to develop and commercialize Vyleesi® (bremelanotide), a melanocortin receptor agonist indicated for th

AMAG Pharmaceuticals, Inc. announced that Edward Myles, Chief Financial and Chief Operating Officer, is leaving the Company.

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that management will participate in the following investor conferences:

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced changes to its medical development organization.

“AMAG’s category-leading treatments are strong strategic complements to our existing therapeutic portfolio,” said Michael Porter, Covis’ chief executive officer.

AMAG Pharmaceuticals, Inc. announced that its Board of Directors has appointed Scott Myers as AMAG’s President and Chief Executive Officer, and member of the Board, effective immediately.

Addition of AMAG’s category leading treatments positions Covis to become a global market leader of therapeutic solutions for life-threatening conditions and chronic illnesses Covis will commence a tender offer to acquire all the outstanding shares of AMAG for a purchase price of $13.75 per share in cash, or approximately $ 647 million, including debt obligations expected to be assumed or repaid net of cash Transaction expected to close in November 2020 post tender offer LUXEMBO